Towards ambient temperature-stable vaccines: The identification of thermally stabilizing liquid formulations for measles virus using an innovative high-throughput infectivity assay

Vaccine

Volumn 29, Issue 31, 2011, Pages 5031-5039

  Schlehuber, Lisa D ^a,c   McFadyen, Iain J ^a   Shu, Yu ^a   Carignan, James ^a   Duprex, W Paul ^a,d   Forsyth, William R ^a   Ho, Jason H ^a   Kitsos, Christine M ^a   Lee, George Y ^a   Levinson, Douglas A ^a   Lucier, Sarah C ^a   Moore, Christopher B ^a   Nguyen, Niem T ^a   Ramos, Josephine ^b   Weinstock, B André ^a   Zhang, Junhong ^b   Monagle, Julie A ^a   Gardner, Colin R ^a   Alvarez, Juan C ^a,e  

^a TransForm Pharmaceuticals   (United States)

^b Lancaster Laboratories   (United States)

^c Avaxia Biologics   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Alkermes   (United States)

Author keywords

Cold chain; Formulation; Gates Foundation Grand Challenges in Global Health; High throughput; Measles; Thermostability

Indexed keywords

MEASLES VACCINE;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG FORMULATION; DRUG STABILITY; DRUG TREATMENT FAILURE; ENVIRONMENTAL TEMPERATURE; FREEZING; HIGH THROUGHPUT SCREENING; INCUBATION TEMPERATURE; MEASLES VIRUS; PRIORITY JOURNAL; STORAGE TEMPERATURE; THERMOSTABILITY; VIROGENESIS; VIRUS ATTENUATION; VIRUS INFECTIVITY;

CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; EXCIPIENTS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MEASLES VACCINE; MEASLES VIRUS; TEMPERATURE;

EID: 79959734631     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.079     Document Type: Article

References (42)

1. [accessed September 20, 2010]. http://www.who.int/en/.
2. Black F.L. Growth and stability of measles virus. Virology 1959, 7:184-192.
3. Newman J.F., Tirrel S., Ullman C., Piatti P.G., Brown F. Stabilizing oral polio vaccine at high ambient temperatures. Vaccine 1995, 13:1431-1435.
4. Cheriyan E. Monitoring the vaccine cold chain. Arch Dis Child 1993, 69:600-601.
5. Cheyne J. Vaccine delivery management. Rev Infect Dis 1989, 11:S617-S622.
6. Lerman S.J., Gold E. Measles in children previously vaccinated against measles. JAMA 1971, 216:1311-1314.
7. Markowitz L.E., Preblud S.T., Fine P.E.M., Orenstein W.A. Duration of live measles vaccine-induced immunity. Pediatr Infect Dis 1990, 9:101-110.
8. Burgess M.A., McIntyre P.B. Vaccines and the cold chain: is it too hot or too cold?. Med J Austr 1999, 171:83-84.
9. Gazmararian J.A., Oster N.V., Green D.C., Schussler L., Howell K., Davis J., et al. Vaccine storage practices in primary care physician offices. Am J Prev Med 2002, 23:246-253.
10. Liddle J.L.M., Harris M.F. How general practitioners store vaccines. A survey in south-western Sydney. Med J Austr 1995, 162:366-368.
11. Nelson C.M., Wibisono H., Purwanto H., Mansyur I., Moniaga V., Widjaya A. Hepatitis B vaccine freezing in the Indonesian cold chain: evidence and solutions. Bull World Health Organ 2004, 82:99-105.
12. Omilabu S.A., Oyefolu A.O., Ojo O.O., Audu R.A. Potency status and efficacy of measles vaccine administered in Nigeria: a case study of three EPI centres in Lagos, Nigeria. Afr J Med Med Sci 1999, 28:209-212.
13. Carrasco R., Dinstrans R., Montaldo I., Medina E., Reyes M., Vergara I., et al. The cold chain and the expanded program on immunization in Chile: an evaluation exercise. Bull Pan Am Health Organ 1982, 16:261-271.
14. Haddad S., Bicaba A., Feletto M., Taminy E., Kabore M., Ouedraogo B., et al. System-level determinants of immunization coverage disparities among health districts in Burkina Faso: a multiple case study. BMC Int Health Hum Rights 2009, 9:S15.
15. Zaffran M. Vaccine transport and storage: environmental challenges. Dev Biol Stand 1996, 87:9-17.
16. Galazka A., Milstien J., Zaffran M Thermostability of vaccines 1998, WHO Vaccine Immune News.
17. Burke C.J., Hsu T.A., Volkin D.B. Formulations, stability, and delivery of live attenuated vaccines for human use. Crit Rev Ther Drug Carrier Syst 1999, 16:1-83.
18. Peetermans J. Factors affecting the stability of viral vaccines. Dev Biol Stand 1996, 87:97-101.
19. [accessed September 20, 2010]. http://www.grandchallenges.org/.
20. Dabbagh A., Gacic-Dobo M., Featherstone D., Strebel P., Okwo-Bele J.M., Hoekstra E., et al. Progress in global measles control and mortality reduction, 2000-2007. JAMA 2009, 301:1430-1431.
21. Griffin D.E., Pan C.H., Moss W.J. Measles vaccines. Front Biosci 2008, 13:1352-1370.
22. Melnick J.L. Thermostability of poliovirus and measles vaccines. Dev Biol Stand 1996, 87:155-160.
23. Ohtake S., Martin R.A., Yee L., Chen D., Kristensen D.D., Lechuga-Ballesteros D., et al. Heat-stable measles vaccine produced by spray drying. Vaccine 2010, 28:1275-1284.
24. WHO Temperature sensitivity of vaccines 2006, WHO Publications. http://www.who.int/vaccines-documents/DocsPDF06/847.pdf.
25. Merck Package Insert for the Attenuvax(R) mono-valent measles vaccine 2006, [cited February 21, 2011]; available from: http://www.merck.com/product/usa/pi_circulars/a/attenuvax/attenuvax_pi.pdf.
26. Burger J.L., Cape S.P., Braun C.S., McAdams D.H., Best J.A., Bhagwat P., et al. Stabilizing formulations for inhalable powders of live-attenuated measles vaccine. J Aerosol Med Pulm Drug Deliv 2008, 21:25-34.
27. Duprex W.P., McQuaid S., Hangartner L., BIlleter M.A., Rima B.K. Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol 1999, 73:9568-9575.
28. Lundholt B.K., Scudder K.M., Pagliaro L.A. Simple technique for reducing edge effect in cell based assays. J Biomol Screen 2003, 8:566-570.
29. Cutchins E.C., Dayhuff T.R. Photoinactivation of Measles virus. Virology 1962, 17:420-425.
30. Plemper R.K., Compans R.W. Mutations in the putative HR-C region of the measles virus F2 glycoprotein modulate syncytium formation. J Virol 2003, 77:4181-4190.
31. O'Doherty U., Swiggard W.J., Malim M.H. Human Immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 2000, 74:10074-10080.
32. Shaneyfelt M.E., Burke A.D., Graff J.W., Jutlia M.A., Hardy M.E. Natural products that reduce rotavirus infectivity identified by a cell-based moderate-throughput screening assay. Viol J 2006, 3.
33. Zhang J.H., Chung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999, 4:67-73.
34. Wallis C., Melnick J.L., Rapp F. Different effects of MgCl2 and MgSO4 on the thermostability of viruses. Virology 1965, 26:694-699.
35. Hamalainen M., Knuuttila M., Svanberg M., Kosinken T. Comparison of the effect of gluconate, lactose, and xylitol on bone recalcification in calcium deficient rats. Bone 2009, 11:429-438.
36. Peterson S.E., Wang S., Ranheim T., Einterz-Owen K. Citrate-mediated disaggregation of rotavirus particles in RotaTeq vaccine. Antiviral Res 2006, 69:107-115.
37. Klamm H., Pollex G., Henning U. Thermal inactivation of different measles virus strains. Acta Virol 1991, 35:200-202.
38. Dilraj A., Cutts F.T., Bennett J.V., Fernandez de Castro J., Cohen B., Coovadia H.M. Persistence of measles antibody two years after revaccination by aerosol or subcutaneous routes. Pediatr Infect Dis J 2000, 19:1211-1213.
39. Wallis C., Melnick J.L. Stabilization of enveloped viruses by dimethyl sulfoxide. J Virol 1968, 2:953-954.
40. Lin W.H., Griffin D.E., Rota P.A., Papania M.J., Cape S.P., Bennett D.J., et al. Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. PNAS 2011, 108:2987-2992.
41. Kissmann J., Ausar S.F., Randolph A., Braun C., Cape S.P., Sievers R.E., et al. Stabilization of measles virus for vaccine formulation. Hum Vaccine 2008, 4:350-359.
42. Vaccine handling and storage. Report of the committee on infectious diseases 2009, 13-17. American Academy of Pediatrics, Elk Grove Village, IL. 28th ed. L.K. Pickering, C.J. Baker, D.W. Kimberlin, S.S. Long (Eds.).